Hsbc Holdings PLC Buys 4,155 Shares of Becton, Dickinson and Company $BDX

Key Points

• Hsbc Holdings PLC increased its stake in Becton, Dickinson and Company by 0.6%, acquiring an additional 4,155 shares to total 661,269 shares valued at approximately $151.19 million.
• Becton, Dickinson reported strong earnings, with $3.68 earnings per share for the last quarter, surpassing analysts' expectations of $3.40, and noted a year-over-year revenue increase of 10.4%.
• The company announced a quarterly dividend of $1.04 per share, with a yield of 2.1%, set to be paid on September 30th to shareholders recorded on September 8th.

Hsbc Holdings PLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 0.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 661,269 shares of the medical instruments supplier's stock after acquiring an additional 4,155 shares during the period. Hsbc Holdings PLC owned about 0.23% of Becton, Dickinson and Company worth $151,189,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. HC Advisors LLC bought a new position in Becton, Dickinson and Company in the first quarter valued at about $229,000. Aptus Capital Advisors LLC grew its position in Becton, Dickinson and Company by 6.8% in the first quarter. Aptus Capital Advisors LLC now owns 14,651 shares of the medical instruments supplier's stock valued at $3,356,000 after acquiring an additional 927 shares during the last quarter. Aviso Financial Inc. grew its position in Becton, Dickinson and Company by 7.7% in the first quarter. Aviso Financial Inc. now owns 21,558 shares of the medical instruments supplier's stock valued at $4,938,000 after acquiring an additional 1,538 shares during the last quarter. Northern Trust Corp grew its position in Becton, Dickinson and Company by 3.2% in the first quarter. Northern Trust Corp now owns 2,811,239 shares of the medical instruments supplier's stock valued at $643,942,000 after acquiring an additional 86,885 shares during the last quarter. Finally, Foyston Gordon & Payne Inc grew its position in Becton, Dickinson and Company by 15.1% in the first quarter. Foyston Gordon & Payne Inc now owns 54,082 shares of the medical instruments supplier's stock valued at $12,388,000 after acquiring an additional 7,075 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president owned 4,575 shares of the company's stock, valued at approximately $783,194.25. This represents a 20.31% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,214 shares of company stock valued at $579,206. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Up 1.5%

Shares of NYSE BDX opened at $197.8470 on Wednesday. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a market cap of $56.71 billion, a PE ratio of 35.58, a P/E/G ratio of 1.46 and a beta of 0.20. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company has a 50-day moving average of $179.13 and a two-hundred day moving average of $196.22.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same period in the previous year, the firm posted $3.50 earnings per share. The company's revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Analyst Ratings Changes

A number of research firms have issued reports on BDX. Bank of America cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price on the stock. in a research report on Thursday, May 1st. The Goldman Sachs Group cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target on the stock. in a report on Friday, May 2nd. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Morgan Stanley boosted their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, William Blair cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Four analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of "Hold" and a consensus target price of $211.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.